ArticleBMC nephrology2014
Serum sclerostin is an independent predictor of mortality in hemodialysis patients.
Article in BMC nephrology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Serum sclerostin in vascular calcification in CKD: a meta-analysis.Renal failure · 2023Pooled it
- Sclerostin, cardiovascular disease and mortality: a systematic review and meta-analysis.International urology and nephrology · 2016Pooled it
- Efficacy and safety of romosozumab in patients with chronic kidney disease and osteoporosis: a narrative review.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Review
- Role of Sclerostin in Cardiovascular System.International journal of molecular sciences · 2025Review
- The serum levels of FGF23, sclerostin, osteoprotegerin do not explain the inverse relationship between coronary calcifications and bone mineral density evaluated using computed tomography.Frontiers in cardiovascular medicine · 2025Article
- Anemia and Mineral Bone Disorder in Kidney Disease Patients: The Role of FGF-23 and Other Related Factors.International journal of molecular sciences · 2024Review
- The Relationship between Sclerostin and Kidney Transplantation Mineral Bone Disorders: A Molecule of Controversies.Calcified tissue international · 2024Review
- Only bioactive forms of PTH (n-oxPTH and Met18(ox)-PTH) inhibit synthesis of sclerostin - evidence from in vitro and human studies.Pflugers Archiv : European journal of physiology · 2024Article
- Serum sclerostin is associated with recurrent kidney stone formation independent of hypercalciuria.Clinical kidney journal · 2024Article
- Association between sclerostin levels and vascular outcomes in kidney transplantation patients.Journal of nephrology · 2023Observational
- FGF-23 and sclerostin in serum and bone of CKD patients.Clinical nephrology · 2023Article
- Is Adynamic Bone Always a Disease? Lessons from Patients with Chronic Kidney Disease.Journal of clinical medicine · 2022Review
- Article
- Sclerostin Protects Against Vascular Calcification Development in Mice.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2022Article
- Review
- Gender-Related Differences in Chronic Kidney Disease-Associated Vascular Calcification Risk and Potential Risk Mediators: A Scoping Review.Healthcare (Basel, Switzerland) · 2021Article
- The Role of Bone Biopsy in the Management of CKD-MBD.Calcified tissue international · 2021Review
- Associations of serum sclerostin and Dickkopf-related protein-1 proteins with future cardiovascular events and mortality in haemodialysis patients: a prospective cohort study.Clinical kidney journal · 2021Article
- Meta-analysis of the association between sclerostin level and adverse clinical outcomes in patients undergoing maintenance haemodialysis.Therapeutic advances in chronic disease · 2021Article
- Relation of Wnt Signaling Pathway Inhibitors (Sclerostin and Dickkopf-1) to Left Ventricular Mass Index in Maintenance Hemodialysis Patients.International journal of nephrology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSclerostin (Scl) has recently emerged as a novel marker of bone remodeling and vascular calcification. However, whether high circulating Scl is also a risk factor for death is not well established. The purpose of this study was to test whether serum Scl would be associated with mortality.
methodswe measured serum Scl in a hemodialysis patients' cohort, which was followed during a ten-year period. Competing risk regression models were applied, as during the follow-up, patients were exposed to both events kidney transplant and death.
resultsNinety-one patients aged 42.3±18.8 years (55% of male gender, 15% of diabetes) were included. During the follow-up, 32 patients underwent kidney transplant and 26 patients died. Non-survivals presented higher FGF23, higher Scl and lower creatinine. There was an association between all-cause mortality and higher Scl (HR=2.2), higher age (HR=1.04) and presence of diabetes (HR=2.27), by competing risk analyses. Even including potential markers of mortality, as creatinine, FGF 23, and gender, Scl, age and diabetes remained significantly related to higher mortality.
conclusionSerum Scl is an independent predictor of mortality in dialysis patients. However, whether clinical interventions to modulate Scl would be able to improve these patients survival needs to be determined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.